| Literature DB >> 35695691 |
William K F Kong1,2, Antonio Salsano3,4, Daniele Roberto Giacobbe5,6, Bogdan A Popescu7, Cécile Laroche8, Xavier Duval9,10, Robert Schueler11, Antonella Moreo12, Paolo Colonna13, Cornelia Piper14, Francisco Calvo-Iglesias15, Luigi P Badano16,17, Ilija Srdanovic18,19, David Boutoille20, Olivier Huttin21,22,23, Elisabeth Stöhr11, Ana Teresa Timóteo24,25,26, Jolanta Justina Vaskelyte27, Anita Sadeghpour28,29, Pilar Tornos30, Leila Abid31, Kian Keong Poh1,2, Gilbert Habib32,33, Patrizio Lancellotti28.
Abstract
AIM: Fatality of infective endocarditis (IE) is high worldwide, and its diagnosis remains a challenge. The objective of the present study was to compare the clinical characteristics and outcomes of patients with culture-positive (CPIE) vs. culture-negative IE (CNIE). METHODS ANDEntities:
Keywords: Blood culture-negative endocarditis; Diagnosis; Endocarditis; Heart valves; Infective endocarditis; Surgery
Mesh:
Year: 2022 PMID: 35695691 PMCID: PMC9459867 DOI: 10.1093/eurheartj/ehac307
Source DB: PubMed Journal: Eur Heart J ISSN: 0195-668X Impact factor: 35.855
Figure 1Kaplan–Meier curves demonstrating freedom from mortality during follow-up in patients with culture-positive and culture-negative endocarditis. Graphs have been plotted by EORP.
Figure 2Kaplan–Meier curves demonstrating freedom from mortality during follow-up in patients with culture-positive and culture-negative endocarditis treated with (A) medical therapy alone and (B) cardiac surgery during index hospitalization.
Baseline clinical characteristics of patients with culture-positive vs. culture-negative infective endocarditis
| Variable | Total | CPIE | CNIE |
|
|---|---|---|---|---|
| Male sex | 2144/3113 (68.9%) | 1808/2590 (69.8%) | 336/523 (64.2%) | 0.01 |
| Age (years) | 59.3 (±18.0) | 60.2 (±17.6) | 54.3 (±19.2) | <0.001 |
| Age ≥65 years | 1443/3113 (46.4%) | 1254/2590 (48.4%) | 189/523 (36.1%) | <0.001 |
|
| ||||
| ( | 25.8 (±6.4) | 25.9 (±6.5) | 25.4 (±5.8) | 0.12 |
| Heart failure | 661/2837 (23.3%) | 536/2337 (22.9%) | 125/500 (25.0%) | 0.32 |
| Ischaemic heart disease (CAD) | 620/2894 (21.4%) | 532/2390 (22.3%) | 88/504 (17.5%) | 0.02 |
| Pre-existing valvular disease | 1067/3113 (34.3%) | 894/2590 (34.5%) | 173/523 (33.1%) | 0.53 |
| Cancer | 359/3085 (11.6%) | 310/2571 (12.1%) | 49/514 (9.5%) | 0.10 |
| Previous stroke/transient ischaemic attack | 340/2857 (11.9%) | 280/2351 (11.9%) | 60/506 (11.9%) | 0.97 |
| Diabetes mellitus | 704/3109 (22.6%) | 608/2586 (23.5%) | 96/523 (18.4%) | 0.01 |
| Arterial hypertension | 1499/3108 (48.2%) | 1276/2585 (49.4%) | 223/523 (42.6%) | 0.005 |
| Congenital disease | 365/3111 (11.7%) | 283/2588 (10.9%) | 82/523 (15.7%) | 0.002 |
| Previous valvular intervention (prosthesis/repair/TAVI) | 1023/3113 (32.9%) | 865/2590 (33.4%) | 158/523 (30.2%) | 0.16 |
| Previous procedure—TAVI | 70/474 (14.8%) | 66/427 (15.5%) | 4/47 (8.5%) | 0.20 |
| Previous procedure—TMVR | 2/95 (2.1%) | 2/81 (2.5%) | 0/14 (0.0%) | 1.0 |
| Previous endocarditis | 274/3113 (8.8%) | 232/2590 (9.0%) | 42/523 (8.0%) | 0.49 |
| COPD/asthma | 317/3108 (10.2%) | 264/2586 (10.2%) | 53/522 (10.2%) | 0.97 |
| Chronic renal failure | 551/3110 (17.7%) | 468/2587 (18.1%) | 83/523 (15.9%) | 0.22 |
| LVEF ( | 55.6 (±12.0) | 55.9 (±11.8) | 54.5 (±12.7) | 0.02 |
| Echocardiography | 2827/2832 (99.8%) | 2329/2333 (99.8%) | 498/499 (99.8%) | 1.0 |
| FDG-PET/CT scan | 518/3113 (16.6%) | 463/2590 (17.9%) | 55/523 (10.5%) | <0.001 |
| Magnetic resonance imaging | 581/3113 (18.7%) | 520/2590 (20.1%) | 61/523 (11.7%) | <0.001 |
| Leucocyte scintigraphy | 38/3113 (1.2%) | 32/2590 (1.2%) | 6/523 (1.1%) | 0.87 |
| Multi-slice computed tomography | 1656/3113 (53.2%) | 1401/2590 (54.1%) | 255/523 (48.8%) | 0.03 |
CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CNIE, culture-negative infective endocarditis; CPIE, culture-positive infective endocarditis; FDG-PET/CT, fluorodeoxyglucose positron emission tomography/computed tomography; LVEF, left ventricular ejection fraction; TAVI, transcatheter aortic valve implantation; TMVR, transcatheter mitral valve repair.
Adverse events at discharge and short- and long-term mortality results in patients with culture-positive vs. culture-negative endocarditis
| Variable | Total | CPIE | CNIE |
|
|---|---|---|---|---|
| Embolic events | 641/3113 (20.6%) | 561/2590 (21.7%) | 80/523 (15.3%) | 0.001 |
| Spondylitis | 145/3113 (4.7%) | 138/2590 (5.3%) | 7/523 (1.3%) | <0.001 |
| Cardiogenic shock | 189/2837 (6.7%) | 149/2337 (6.4%) | 40/500 (8.0%) | 0.19 |
| Septic shock | 287/3113 (9.2%) | 246/2590 (9.5%) | 41/523 (7.8%) | 0.23 |
| Glomerulonephritis | 89/3094 (2.9%) | 69/2571 (2.7%) | 20/523 (3.8%) | 0.16 |
| Cerebral haemorrhage | 71/3113 (2.3%) | 61/2590 (2.4%) | 10/523 (1.9%) | 0.54 |
| Mycotic aneurysm | 58/3113 (1.9%) | 48/2590 (1.9%) | 10/523 (1.9%) | 0.93 |
| Acute renal failure | 548/3113 (17.6%) | 441/2590 (17.0%) | 107/523 (20.5%) | 0.06 |
| Persistent fever | 350/2837 (12.3%) | 287/2337 (12.3%) | 63/500 (12.6%) | 0.84 |
| Increasing vegetation size | 201/3113 (6.5%) | 170/2590 (6.6%) | 31/523 (5.9%) | 0.59 |
| New abscess | 193/3113 (6.2%) | 174/2590 (6.7%) | 19/523 (3.6%) | 0.008 |
| AV block | 128/2837 (4.5%) | 111/2337 (4.7%) | 17/500 (3.4%) | 0.19 |
| Thrombopenia | 214/2837 (7.5%) | 181/2337 (7.7%) | 33/500 (6.6%) | 0.38 |
| Heart failure | 370/2579 (14.3%) | 295/2161 (13.7%) | 75/418 (17.9%) | 0.02 |
| Valve or prosthetic dysfunction | 439/2582 (17.0%) | 352/2164 (16.3%) | 87/418 (20.8%) | 0.02 |
| Length of stay | 42.1 (±39.9) | 42.3 (±38.7) | 41.1 (±45.6) | 0.03 |
| Death at 30 days | 341/3113 (11.0%) | 263/2590 (10.2%) | 78/523 (14.9%) | 0.001 |
| In-hospital death | 529/3113 (17.0%) | 424/2590 (16.4%) | 105/523 (20.1%) | 0.04 |
|
| ||||
| Overall | 57/1605 (3.6%) | 51/1341 (3.8%) | 6/264 (2.3%) | 0.22 |
| Medical therapy | 30/742 (4.0%) | 28/621 (4.5%) | 2/121 (1.7%) | 0.21 |
| Surgical therapy | 27/859 (3.1%) | 23/718 (3.2%) | 4/141 (2.8%) | 1.00 |
|
| ||||
| Overall | 129/1567 (8.2%) | 111/1319 (8.4%) | 18/248 (7.3%) | 0.54 |
| Medical therapy | 74/716 (10.3%) | 63/602 (10.5%) | 11/114 (9.6%) | 0.79 |
| Surgical therapy | 55/847 (6.5%) | 48/716 (6.7%) | 7/131 (5.3%) | 0.56 |
|
| ||||
| Overall | 153/3113 (4.9%) | 130/2590 (5.0%) | 23/523 (4.4%) | 0.55 |
| Medical therapy | 87/1608 (5.4%) | 71/1322 (5.4%) | 16/286 (5.6%) | 0.88 |
| Surgical therapy | 66/1488 (4.4%) | 59/1259 (4.7%) | 7/229 (3.1%) | 0.27 |
|
|
| |||
| Overall | 719/3113 (23.1%) | 584/2590 (22.5%) | 135/523 (25.8%) | 0.04 |
| Survival rate (standard error) | 74.5% (0.8%) | 75.0% (0.9%) | 71.6% (2.1%) | |
| Medical therapy | 474/1608 (29.5%) | 380/1322 (28.7%) | 94/286 (32.9%) | 0.04 |
| Survival rate (standard error) | 67.6% (1.2%) | 68.5% (1.4%) | 63.5% (3.1%) | |
| Surgical therapy | 236/1488 (15.9%) | 199/1259 (15.8%) | 37/229 (16.2%) | 0.09 |
| Survival rate (standard error) | 96.7% (0.6%) | 96.6% (0.7%) | 97.1% (1.4%) | |
AV, atrioventricular; CNIE, culture-negative infective endocarditis; CPIE: culture-positive infective endocarditis; IE: infective endocarditis.
Results from actuarial survival curves: survival rate, standard error, and log-rank tests (see text and Figures 1 and 2).
Multivariable Cox proportional hazard models for prediction of 30-day and 1-year mortality
| 30-day mortality | 1-year mortality | |||
|---|---|---|---|---|
| Variable | Hazard ratio (95% CI)[ |
| Hazard ratio (95% CI)[ |
|
| Surgery | 0.33 (0.25–0.43) | <0.001 | 0.49 (0.41–0.58) | <0.001 |
| Chronic heart failure | 1.69 (1.32–2.17) | <0.001 | 1.62 (1.36–1.92) | <0.001 |
| Chronic renal failure | — | — | 1.51 (1.25–1.82) | <0.001 |
| Diabetes | — | — | 1.22 (1.02–1.46) | 0.03 |
|
| ||||
| Cerebral embolism | 1.59 (1.16–2.18) | 0.004 | — | — |
| Congestive heart failure | 1.35 (1.04–1.74) | 0.025 | — | — |
| Conduction abnormality on ECG (ref: no AV block) | <0.001 | <0.001 | ||
| 1st-degree AV block | 0.71 (0.43–1.16) | 0.60 (0.43–0.84) | ||
| 2nd-degree AV block | 3.68 (1.16–1.66) | 2.77 (1.37–5.61) | ||
| 3rd-degree AV block | 2.64 (1.55–4.47) | 1.65 (1.12–2.43) | ||
|
| ||||
| Aortic valve | 1.65 (1.30–2.11) | <0.001 | — | — |
| Mitral valve | 1.69 (1.33–2.15) | <0.001 | — | — |
|
| ||||
| MRI | 0.43 (0.28–0.65) | <0.001 | — | — |
| PET scan | 0.38 (0.22–0.63) | <0.001 | — | — |
|
| ||||
| Congestive heart failure | 1.59 (1.20–2.11) | 0.001 | — | — |
| Cardiogenic shock | 1.96 (1.43–2.67) | <0.001 | 2.41 (1.91–3.04) | <0.001 |
| Cerebral haemorrhage | 2.18 (1.32–3.61) | 0.002 | 2.84 (1.91–4.22) | <0.001 |
| Embolic events | 1.83 (1.41–2.38) | <0.001 | — | — |
| Acute renal failure | — | — | 1.54 (1.28–1.84) | <0.001 |
| Septic shock | 2.97 (2.24–3.93) | <0.001 | 3.45 (2.79–4.25) | <0.001 |
| CNIE | 1.27 (0.97–1.66) | 0.08 | 1.28 (1.04–1.56) | 0.02 |
AV, atrioventricular; CI, confidence interval; CNIE, culture negative infective endocarditis; ECG, electrocardiogram; MRI, magnetic resonance imaging; PET, positron emission tomography.
Sample size: N = 2600/3113 (83.5%). Goodness of fit test: P = 0. 02; Concordance = 0.82; Global Schoenfeld residual test P = 0.67.
Sample size: N = 2639/3113 (84.8%). Goodness of fit test: P < 0.001; Concordance = 0.75; Global Schoenfeld residual test P = 0.02.
P-value corresponds to the results of Wald test.